Sigyn Therapeutics, Inc. SIGY

SIGY Company Overview

Sigyn Therapeutics, Inc. is a publicly traded biotechnology company focused on developing extracorporeal blood purification technologies intended to treat life‑threatening diseases. The company operates within the medical device and biotechnology industries, with a particular emphasis on therapies targeting excessive inflammatory mediators, circulating toxins, pathogens, and disease‑associated biological factors present in blood. Its core product candidate, Sigyn Therapy, is designed to be used outside the body to filter harmful substances from a patient’s bloodstream.

The company’s primary revenue drivers are currently research and development activities rather than commercial sales, as its technologies remain in development and clinical evaluation stages. Sigyn Therapeutics primarily targets hospital and critical‑care settings, including intensive care units treating conditions such as sepsis, acute inflammatory disorders, and certain oncology‑related indications. The company was founded in the early 2000s and has evolved from a broader life‑sciences focus into a specialized developer of blood purification platforms, maintaining status as a development‑stage company according to its SEC filings.